Few longevity supplements have generated as much excitement — or as much criticism — as alpha ketoglutarate. A simple metabolite from the Krebs cycle, AKG sits at the crossroads of energy metabolism, epigenetic regulation, and collagen biology. Mouse studies have shown genuinely impressive healthspan and lifespan extension. And then in 2021, a commercial product called Rejuvant (calcium alpha-ketoglutarate) was associated with a claim of "eight years of biological age reversal" in humans — a headline that went viral and hardened skepticism in equal measure.
This article separates the well-supported AKG biology from the overhyped human data. AKG is a mechanistically rich target worth studying. It is also a cautionary example of how open-label observational data and proprietary biological-age clocks can combine to produce claims that outrun their evidence base.
What Is Alpha-Ketoglutarate?
Alpha-ketoglutarate (AKG, also called 2-oxoglutarate) is a five-carbon dicarboxylic acid that is one of the central intermediates of the tricarboxylic acid (TCA, or Krebs) cycle — the mitochondrial engine that converts acetyl-CoA from carbohydrate, fat, and protein into the reducing equivalents that power ATP synthesis. AKG sits between isocitrate and succinyl-CoA in the cycle and is produced by isocitrate dehydrogenase (IDH).
But AKG does more than turn metabolic wheels. It is also:
- A required cofactor for 2-oxoglutarate-dependent dioxygenases, a large family of enzymes that includes the TET (ten-eleven translocation) DNA demethylases, the JmjC-domain histone demethylases, the prolyl hydroxylases that regulate HIF-1-alpha, and the collagen prolyl and lysyl hydroxylases.
- A nitrogen balance regulator, accepting amino groups in glutamate dehydrogenase reactions.
- A substrate for glutamine synthesis and an anaplerotic refueler of the TCA cycle.
That first role — cofactor for TET and JmjC enzymes — is why AKG is mechanistically interesting for aging. TET enzymes demethylate DNA; JmjC enzymes demethylate histones. Both shape the epigenome. AKG concentrations decline with age in many tissues, which could in principle contribute to the epigenetic drift that clocks like Horvath and GrimAge measure — one of the hallmarks of aging.
The Science: How AKG Could Slow Aging
The mechanistic case for AKG in longevity rests on four pillars:
- Epigenetic maintenance. Higher AKG availability supports TET and JmjC activity, potentially counteracting age-related accumulation of aberrant DNA and histone methylation.
- Collagen and extracellular matrix. Prolyl 4-hydroxylase (required for stable collagen triple helix) is AKG-dependent. AKG-deficient cells make structurally unstable collagen.
- Energy metabolism. AKG supplementation can feed the TCA cycle and support NADH/NAD+ balance.
- mTOR and autophagy. In C. elegans, AKG extends lifespan by inhibiting ATP synthase and downstream TOR signaling (Chin et al. 2014, Nature) — a pathway shared with rapamycin and caloric restriction.
Taken together, AKG touches several longevity-relevant pathways simultaneously. That plurality is why it's worth studying and why it's hard to evaluate rigorously — improvements in any single readout could reflect any of several mechanisms.
The Evidence: Mouse Data Strong, Human Data Weak
Chin et al. 2014 (Nature). The foundational study. In C. elegans, AKG supplementation extended lifespan by about 50% through ATP synthase inhibition and TOR pathway suppression. This established AKG as a legitimate aging target in a model organism.
Asadi Shahmirzadi et al. 2020 (Cell Metabolism). A landmark mouse study from the Kennedy lab at the Buck Institute. Calcium AKG (CaAKG) added to chow in middle-aged (18-month-old) mice compressed morbidity, reduced frailty scores, and extended median lifespan — with particularly strong healthspan effects in females. Mice on CaAKG had lower inflammation and improved functional scores. The key framing: AKG compressed the period of end-of-life decline rather than dramatically extending maximum lifespan. This is actually a desirable profile — more healthy years, less drawn-out dying.
Shahmirzadi et al. 2021 (Aging). This is the paper that launched the human controversy. The authors reported an observational analysis of 42 humans taking Rejuvant (a branded CaAKG supplement from Ponce de Leon Health) and found an average reduction of roughly eight years in biological age as estimated by the TruMe epigenetic clock after about seven months of supplementation.
The problem is that this was not a randomized controlled trial. It was open-label, self-selected supplementation with a commercially sold product, using a proprietary biological-age clock. The confounds are numerous: (1) people who choose to take longevity supplements often adopt other healthy behaviors; (2) the TruMe clock's validation and comparison to established clocks like Horvath, GrimAge, and DunedinPACE is limited; (3) test-retest noise in epigenetic clocks can be several years by itself; (4) regression to the mean in self-selected high-biological-age individuals; (5) no placebo control.
Several epigenetic-aging researchers have publicly pushed back on the headline claim, noting that a well-designed RCT with a validated clock would be required to substantiate anything like the reported effect. As of 2026, such a trial has not reported out.
Ongoing human trials. Smaller RCTs of AKG in aging adults are in progress. The Buck Institute and collaborators have been running controlled studies designed to answer the question the 2021 observational paper could not. Early readouts on inflammatory markers and physical function are expected in 2026-2027.
Current Clinical Status: Who's Working On This
The AKG longevity space includes:
- Ponce de Leon Health — the company behind Rejuvant, which brought CaAKG into the consumer supplement market with Kennedy and others associated.
- The Buck Institute (Kennedy lab) — ongoing mechanistic and clinical research on AKG and combinations.
- Academic groups at Washington University, University of Washington, and USC exploring AKG in various aging contexts.
- Supplement brands selling CaAKG or AAKG (arginine alpha-ketoglutarate, originally marketed for athletic performance).
The distinction between calcium AKG (used in the aging trials) and arginine AKG (AAKG, popular in bodybuilding) matters. They have different pharmacokinetics and different evidence bases. The mouse longevity data and the controversial Rejuvant observational paper used CaAKG. AAKG has been studied for vasodilation and exercise performance, not longevity.
Connection to Gene Editing & Peptides
AKG's epigenetic mechanism links it directly to the broader rejuvenation conversation.
- Epigenetic reprogramming overlap. AKG-dependent TET and JmjC enzymes are the same machinery that is co-opted during partial reprogramming with Yamanaka factors. If reprogramming represents a forceful reset of the epigenome, adequate AKG is the metabolic substrate that makes that reset enzymatically possible.
- Peptide stacking questions. Some protocols combine AKG with longevity peptides. Mechanistic overlap exists, but no trial has formally tested these combinations.
- Gene editing angle. In principle, genes that regulate AKG production or sensing could be edited to raise endogenous AKG — but this is pure speculation.
- Clock context. If you're going to argue that AKG reverses biological age, you need to do it with rigorous clocks. The 2021 Rejuvant paper's reliance on a proprietary clock is a cautionary example; the current state of epigenetic clocks offers better tools.
Limitations
- Human data are weak. The much-publicized eight-year biological age claim came from an open-label observational study using a non-standard clock. That is not the level of evidence people typically associate with "proven."
- Commercial entanglement. Several of the authors of the 2021 paper had relationships with Ponce de Leon Health. Financial conflicts of interest don't invalidate science but require disclosure and skepticism.
- Dose and pharmacokinetics. Oral AKG has limited bioavailability; CaAKG may partially bypass this through sustained release, but tissue-level AKG pharmacokinetics in humans are poorly characterized.
- Species differences. Mouse lifespan studies are suggestive but often fail to translate. The history of longevity drug development is littered with compounds that worked in mice and didn't in humans.
- Cost. Rejuvant and similar CaAKG products are considerably more expensive than generic AKG.
- No head-to-head comparisons. We lack trials comparing AKG against other longevity interventions (rapamycin, metformin, GlyNAC, senolytics).
The honest bottom line for 2026: AKG has a real mechanistic rationale and good mouse data. The human evidence is preliminary and in places overstated. It may be a useful longevity intervention; it is not yet proven to be one.
FAQ
Did Rejuvant really reverse biological age by 8 years?
The 2021 paper reported that average, but it was an open-label, self-selected, observational analysis using a proprietary clock. The design cannot support a causal conclusion. An RCT using validated clocks has not yet shown that effect.
What's the difference between CaAKG and AAKG?
Calcium alpha-ketoglutarate (CaAKG) is the form studied in the Buck Institute mouse longevity paper and the Rejuvant observational study. Arginine alpha-ketoglutarate (AAKG) is a different salt marketed historically for exercise performance. Longevity claims apply specifically to CaAKG.
Is alpha-ketoglutarate safe?
Short-term safety of CaAKG at studied doses appears good. Long-term safety in healthy adults is not well characterized. AKG feeds multiple pathways, and chronic supraphysiological supplementation of a central metabolite always deserves caution.
Does AKG work like rapamycin?
Partially. In C. elegans, AKG suppresses TOR signaling, which overlaps with rapamycin's mechanism. In mice, AKG's effects include reduced inflammation and improved healthspan but are not identical to rapamycin's profile.
Should I take AKG?
This article does not give supplement recommendations. The mechanistic rationale is interesting; the human RCT evidence is weak. Anyone considering it should discuss with a physician and understand that the strong claims exceed the data.
How does AKG relate to fasting and caloric restriction?
AKG levels fluctuate with fasting and nutrient status. Some mouse data suggest AKG supplementation recapitulates aspects of caloric restriction biology, but it is not a CR mimetic in the same rigorous sense as rapamycin.
Further Learning
- Epigenetic Clocks and Biological Age — essential context for interpreting AKG claims
- Hallmarks of Aging Explained — where metabolic and epigenetic aging fit
- Yamanaka Factors and Partial Reprogramming — the complementary rejuvenation strategy
